Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,089 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastric Neoplasm Clear all
Completed No phase listed Observational

Hereditary Colorectal and Associated Tumor Registry Study

NCT00633607
View directory record Official record
Conditions
Lynch Syndrome, FAP, Hereditary Diffuse Gastric Cancer, Juvenile Polyposis Syndrome, Peutz-Jeghers Syndrome
Interventions
Research Registry
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

NCT01046864
View directory record Official record
Conditions
Gastro-Intestinal Cancer
Interventions
5-FU, Leucovorin, Irinotecan, Brivanib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Dallas, Texas • Temple, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2014 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated Not applicable Interventional Results available

Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach

NCT02358863
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Modified FOLFOX6, Docetaxel/Capecitabine, Cisplatin/Irinotecan, Cisplatin/Docetaxel, IRI/EPI, EPI/Docetaxel, Irinotecan/Docetaxel, Docetaxel
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 6, 2018 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study in Patients With Gastric Cancer

NCT00400179
View directory record Official record
Conditions
Gastric Cancer
Interventions
S-1/Cisplatin, 5-FU/cisplatin
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,053 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
32
States / cities
Huntsville, Alabama • Burbank, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1 Interventional Results available

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

NCT03028103
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma, Mantle Cell Lymphoma, Advanced Solid Tumor, Marginal Zone Lymphoma
Interventions
Tazemetostat, Fluconazole, Omeprazole, Repaglinide
Drug
Lead sponsor
Epizyme, Inc.
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
3
States / cities
Tucson, Arizona • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 23, 2026, 1:41 PM EDT
Active, not recruiting Phase 2 Interventional

Tadalafil Effect + Chemotherapy in Resectable Gastric/GEJ Cancer

NCT05709574
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Interventions
Tadalafil 20 MG
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors

NCT02948946
View directory record Official record
Conditions
Gastroenteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm
Interventions
NETest
Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2021 · Synced Oct 23, 2026, 1:41 PM EDT
Enrolling by invitation Phase 1 Interventional

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07218003
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer, Triple Negative Breast Cancer (TNBC), Urothelial Carcinoma Bladder, Gastroesophageal Junction (GEJ) Adenocarcinoma, Esophageal Squamous Cell Cancer, Gastric Cancer, Cancer, Solid Tumors (Phase 1)
Interventions
RNDO-564, Pembrolizumab
Drug
Lead sponsor
Rondo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
11
States / cities
San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1 Interventional

Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer

NCT00654160
View directory record Official record
Conditions
Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Gastrointestinal Stromal Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions
fluorouracil, irinotecan hydrochloride, leucovorin calcium, pharmacogenomic studies, pharmacological study
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 120 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 23, 2026, 1:41 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers

NCT07544589
View directory record Official record
Conditions
Colorectal Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Biliary Tract Carcinoma
Interventions
DISP-10
Biological
Lead sponsor
Dispatch Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2046
U.S. locations
7
States / cities
Duarte, California • Newport Beach, California • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

NCT07001748
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel
Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
78
States / cities
Irvine, California • Los Angeles, California • Orange, California + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 3 Interventional Results available

PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers

NCT04616768
View directory record Official record
Conditions
Cancer, Lung Cancer, Gastro-intestinal
Interventions
PRO questionnaire, Step monitoring, Active nudge text feedback, PROStep Dashboard (clinicians)
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 23, 2026, 1:41 PM EDT
Recruiting Phase 2 Interventional

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211
View directory record Official record
Conditions
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
Interventions
Datopotamab deruxtecan (Dato-DXd), Capecitabine, 5-Fluorouracil, Volrustomig, Carboplatin, Bevacizumab, Rilvegostomig, Prednisone/ prednisolone, Cisplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • Santa Rosa, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed No phase listed Observational

Solid Tumor Cancer Surgery With or Without Intraoperative Imaging: A Registry

NCT02852252
View directory record Official record
Conditions
Bladder Cancer, Gastric Cancer
Interventions
OTL38, ICG
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 23, 2026, 1:41 PM EDT
Active, not recruiting Phase 1 Interventional

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

NCT06544655
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BMS-986484, Nivolumab, Oxaliplatin, Capecitabine, Fluorouracil, Calcium folinate
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Tucson, Arizona • Los Angeles, California • Grand Rapids, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Recruiting Phase 2 Interventional

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT06172478
View directory record Official record
Conditions
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer, Non-small Cell Lung Cancer (NSCLC), Lung Cancer, Breast Cancer
Interventions
HER3-DXd
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
13
States / cities
Duarte, California • New Haven, Connecticut • Kissimmee, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed No phase listed Observational

Immunohistochemical & Immunoblot Analysis of NIS (Na+/I-Symporter) in Archival & Frozen Tissue Sample

NCT00568438
View directory record Official record
Conditions
Breast Cancer, Stomach Neoplasms, Salivary Gland Neoplasms, Thyroid Cancer
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery

NCT00991952
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIA Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
Interventions
alvocidib, irinotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
5
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 23, 2026, 1:41 PM EDT
Terminated No phase listed Observational

CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice

NCT02900248
View directory record Official record
Conditions
Neoplasms, Lung Neoplasms, Colon Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Prostate Neoplasms, Kidney Neoplasms, Liver Neoplasms, Rectal Neoplasms, Hematologic Neoplasms, Multiple Myeloma, Myelodysplastic Syndromes, Ovarian Neoplasms, Bladder Neoplasms, Testicular Neoplasms, Endometrial Neoplasms, Brain Neoplasms, Biliary Tract Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Skin Neoplasms, Melanoma, Gastric Neoplasms, Anal Neoplasms, Sarcoma
Interventions
Provider determined
Other
Lead sponsor
CureOne
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Idaho Falls, Idaho
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional

Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon

NCT00010283
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
beclomethasone dipropionate
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
5 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 2, 2010 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 2 Interventional Results available

Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric Cancer

NCT01522768
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Afatinib and Paclitaxel
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
9
States / cities
Los Angeles, California • Boston, Massachusetts • Basking Ridge, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 23, 2026, 1:41 PM EDT
Active, not recruiting Phase 2 Interventional

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

NCT04069273
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Interventions
Pembrolizumab Monotherapy, Ramucirumab, Paclitaxel
Drug
Lead sponsor
Harry H Yoon
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

NCT03008278
View directory record Official record
Conditions
Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
Interventions
Olaparib, Ramucirumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
32
States / cities
Corona, California • Duarte, California • Lancaster, California + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 23, 2026, 1:41 PM EDT
Completed Not applicable Interventional

Clinical Utility Evidence for TissueCypher®

NCT05200325
View directory record Official record
Conditions
Gastro-Intestinal Disorder, Barrett Esophagus
Interventions
Educational materials for TissueCypher
Other
Lead sponsor
Qure Healthcare, LLC
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 23, 2026, 1:41 PM EDT